Background: When the prekallikrein-high molecular weight kininogen complex is bound to endothelial cells, prekallikrein is stoichiometrically converted to kallikrein because of release of heat shock protein-90 (Hsp90). Although bradykinin formation is typically initiated by factor XII autoactivation, it is also possible to activate factor XII either by kallikrein, thus formed, or by plasmin. Objective: Because attacks of hereditary angioedema can be related to infection and/or exposure to estrogen, we questioned whether estrogen or cytokine stimulation of endothelial cells could augment release of Hsp90 and prekallikrein activation. We also tested release of profibrinolytic enzymes, urokinase, and tissue plasminogen activator (TPA) as a source for plasmin formation. Methods: Cells were stimulated with agonists, and secretion of Hsp90, urokinase, and TPA was measured in the culture supernatants by ELISA. Activation of the prekallikrein-HK complex was measured by using pro-phe-arg-p-nitroanilide reflecting kallikrein formation. Results: Hsp90 release was stimulated with optimal doses of estradiol, IL-1, and TNF-a (10 ng/mL) from 15 minutes to 120 minutes. TPA release was not augmented by any of the agonists tested but urokinase was released by IL-1, TNF-a, and thrombin (positive control), but not estrogen. Augmented activation of the prekallikrein-HK complex to generate kallikrein was seen with each agonist that releases Hsp90. Addition of 0.1% factor XII relative to prekallikrein-HK leads to rapid formation of kallikrein; factor XII alone does not autoactivate. Conclusions: IL-1, TNF-a, and estrogen stimulate release of Hsp90 and augment activation of the prekallikrein-HK complex to generate kallikrein and bradykinin. IL-1 and TNF-a stimulate release of urokinase, which can convert plasminogen to plasmin and represents a possible source for plasmin generation in all types of hereditary angioedema, but particularly hereditary angioedema with normal C1 inhibitor with a factor XII mutation. Both kallikrein and plasmin activate
The timing of attacks of angioedema in patients with the hereditary forms (types I and II; C1 inhibitor deficiency) or type III (hereditary angioedema with normal C1 inhibitor [HAE-N]) is, in general, unpredictable. However, a number of ''triggers'' that seem to associate with the onset of angioedema include physical trauma, infection, stress including emotional stress, and use of estrogen. How these actually lead to an augmented surge in bradykinin production is not clear, but the association is assumed, because the final step in angioedema formation is the interaction of bradykinin with venular B2 receptors to produce vasodilation and an increase in permeability. It is known that estrogen raises blood levels of factor XII, [1] [2] [3] which can enhance bradykinin formation once initiation of an event occurs. Trauma, for example, may expose plasma or interstitial fluid to vessel wall constituents such as collagen and sulfated proteoglycans. Although type I collagen has been reported to function as a ''surface'' to initiate activation of factor XII, 4 the role of collagen itself, when highly purified, has been controversial 5, 6 ; highly sulfated proteoglycans (heparin, heparan sulfate, or chondroitin sulfates), however, clearly bind factor XII to initiate factor XII autoactivation 7 as a first step to bradykinin formation. [8] [9] [10] We have approached this question using a model in which the constituents of the bradykinin-forming cascade are bound to the cell surface and the endothelial cells stimulated in such a way as to approximate what might occur during an initiating event. We have chosen conditions of cytokine stimulation with IL-1 and TNF-a, estrogen, and bradykinin itself as cell stimuli and focus on release of heat shock protein 90 (Hsp90), a transport protein that can be expressed at the cell surface and secreted into the milieu. Hsp90 acts on the complex of prekallikrein-high molecular weight kininogen (prekallikrein-HK) to generate the enzyme kallikrein. 11 Kallikrein, in turn, activates factor XII and cleaves HK to release bradykinin. Because plasmin is an alternative enzyme capable of activating factor XII, 12 we also monitored secretion of profibrinolytic enzymes urokinase and TPA.
METHODS Materials
Human plasma proteins, HK, prekallikrein, and factor XII, were purchased from Enzyme Research Laboratories (South Bend, Ind). Collection of citrated plasma. Citrated plasma used in this study was separated by centrifugation of freshly collected blood at 2000 rpm for 10 minutes at 48C. Samples were immediately aliquoted and stored at 2808C.
Endothelial cell culture. Human umbilical vein endothelial cells, used in all cell-dependent experiments, were isolated as described earlier 13 and cultured in gelatin-coated dishes in endothelial growth medium (EGM Bullet kit, Clonetics, San Diego, Calif). For cell stimulation experiments, cells were grown in 24-well plates in 0.5 mL culture medium. For prekallikrien and factor XII activation assays, the cells were subcultured into 96-well plates in 0.2 mL of culture medium. The cells were identified as endothelial cells by their distinct cobblestone morphology and interaction with antiserum to Von Willebrand's factor.
14 All the cells were used at the third or fourth cell passage.
Direct binding of HK and prekallikrein to Hsp90.
Purified Hsp90 was coated onto microtiter plates by incubating in 0.1 mol/L Na 2 CO 3 , pH 9.6, overnight at 48C. After blocking with 1% BSA in PBS, various concentrations of HK and prekallikrein in Hepes buffered saline containing 0.5% BSA and 50 mM zinc chloride were incubated up to 2 hours at 378C. The relative binding of each protein was determined using specific antibodies followed by alkaline phosphatase-conjugated secondary antibodies and color development using phosphatase-specific substrate.
SDS-polyacrylamide gel electrophoresis and Western blot. Samples were collected in SDS sample buffer containing 5% 2-mercaptoethanol. SDS-polyacrylamide gel electrophoresis was performed using the buffer system of Laemmli. 15 Gradient gels (4% to 20%) were used for separation of proteins. After electrophoresis, the separated proteins from gels were transferred to nitrocellulose membranes overnight. The membranes were then incubated with blocking buffer (1% BSA in PBS) for 1 hour and probed with mAbs for an additional 1 hour. Bound probes were visualized by incubating the membranes with alkaline phosphatase-conjugated secondary antibodies followed by color development in 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium.
Prekallikrein activation assay
PK activation assays were performed in ''assay buffer'' (10 mM Hepes, 137 mM NaCl, 4 mM KCl, 11 mM D-glucose, 1 mg/mL RIA grade BSA), with a kallikrein-specific substrate (0.6 mM S2302) in 96-well disposable polystyrene microtiter plates (Dynatech Laboratories, Chantilly, Va) pretreated with 1% polyethylene glycol (Aquacide III, Calbiochem, La Jolla, Calif). Just before the assay all the proteins were treated with 2.0 mM APMSF for 90 minutes at pH 5.5, after which they were diluted 1:100 with assay buffer and incubated for 30 minutes to allow for the decomposition of any unreacted APMSF at the neutral pH. Assay buffer was also pretreated with 0.4 mM APMSF to inactivate any serene protease activity present in the RIA grade BSA. HK and PK were incubated in the assay buffer in the presence of S2302 and the kallikrein activity was determined by the color development. The absorbance (OD at 405 nm) was monitored at room temperature on a Molecular Devices (Sunnyvale, Calif) THERMOmax microplate reader.
ELISA to measure levels of Hsp90, urokinase, and tissue-type plasminogen activator. ELISA kits for the measurement of Hsp90 were from Enzo Life Sciences, Inc (Farmingdale, NY). Assay kits for urokinase and TPA were obtained from Cloud-Clone Corp (Houston, Tex). All assays were performed according to the manufacturer's recommendations.
Statistical analysis
Statistical analysis was performed using paired t test. Values obtained from each experimental condition (time course and dose-response) were compared with corresponding control values. A P value of less than .05 was considered significant.
RESULTS

Binding of HK and prekallikrein to Hsp90
The interaction of HK-prekallikrein with Hsp90 is stoichiometric and also dependent on zinc ion 11 ; however, it is not clear whether Hsp90 binds to HK or prekallikrein. We therefore examined the ability of microtiter plates coated with Hsp90 (5 mg/mL) to bind either HK or prekallikrein. As can be seen in Fig 1, Hsp90 binds primarily to HK (saturated at 5 mg/mL), thereby forming a trimolecular complex with HK-prekallikrein although it interacts with prekallikrein as well. There are no interactions in the absence of zinc.
Hsp90 release from activated endothelial cells
Human umbilical vein endothelial cells were incubated with increasing doses of IL-1, TNF-a, and estradiol and the release of Hsp90 was measured by ELISA using monospecific antibody. An optimal dose was, coincidentally, about 10 ng/mL in each case (Fig 2, A) , which is within the range of previous reports. 16, 17 A time course of cell activation is shown in Fig 2, B. Compared with the control, there was increased release at 15, 30, 60, and 120 minutes using estradiol with a clear dose-response, and similar increases are seen at 15, 30, and 60 minutes using IL-1. For the latter, the peak level decreased at 120 minutes. The result with TNF-a was not as robust, but was increased at the 60-and 120-minute time points. We know that estrogen and infection can be triggers of angioedema in types I and II HAE and most cases of type III (HAE with normal C1 inhibitor) are strikingly estrogen dependent. [18] [19] [20] This provides one mechanism by which bradykinin generation could be linked to these substances.
Kallikrein formation on IL-1-b-, TNF-a-, and estrogen-stimulated endothelial cells Based on the above findings, it was evident that endothelial cell stimulation can release Hsp90. Next, we questioned whether it can be connected to the formation of bradykinin or as a surrogate, the conversion of prekallikrein to kallikrein. The results are shown in Fig 3 where we compared prekallikrein alone, HK-prekallikrein alone, and HK-prekallikrein stimulated with IL-1b, TNF-a, or estrogen. Stimulation of endothelial cells with IL-1-b, TNF-a, and estrogen does not augment kallikrein formation when prekallikrein alone is bound to the cell. In contrast, HK-prekallikrein does slowly activate but there is augmentation of HK-prekallikrein conversion to kallikrein when the cells were stimulated by IL-1-b, estrogen, or TNF-a and all these are strikingly similar at the 10 ng/mL concentrations J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 1 used. The formation of kallikrein by Hsp90 further suggests the possibility of factor XII activation by this process. Once factor XII is added, activation is so rapid it is difficult to know just how it started but very little factor XII activation is seen when HK is absent even if prekallikrein is supplied (Fig 4) .
Release of urokinase and tissue plasminogen activator from IL-1-b2, TNF-a2, and estrogenstimulated endothelial cells Focus on a role for fibrinolysis as a contributor to angioedema has evolved in recent years. Plasmin is known to enzymatically were incubated in Hsp90 (5 mg/mL)-coated plates for 1 hour and probed with polyclonal antibodies to each followed by secondary antibody and color development. The binding was performed in the presence or absence of 50 mM zinc chloride. Each concentration was in duplicate and the assay was performed at 3 times.
FIG 2.
Hsp90 release from activated endothelial cells. Cells were grown in 24-well plate with 0.5 mL medium. When confluent, the cells were washed and changed to serum-free medium for treatment with bradykinin, IL-1-b, TNF-a, and estradiol and incubated at 378C. A, Dose-response: Cells were treated for 2 hours with varying concentrations of each compound as indicated and the supernatant was collected and assayed by ELISA. The graph represents mean 6 SD of 3 separate experiments. Values that are significantly higher than control are indicated with asterisks (*P < .05). B, Time course: Samples were collected at indicated times and the levels of Hsp90 released were measured by ELISA. The graph represents mean 6 SD of 3 separate experiments. *Indicate values that are significantly higher than control (P < .05) at a comparable time point.
activate factor XII 12 and elevated levels of D-dimer are reported in many types of urticaria and angioedema, [21] [22] [23] including types I and II HAE. 23 Furthermore, we note particularly low levels of a controller inhibitor of fibrinolysis in HAE with normal C1 inhibitor, 24 namely, plasminogen activator inhibitor-2 (PAI-2), which inhibits urokinase primarily, 25 and tissue plasminogen activator (TPA) to a lesser degree. This prompted us to examine the secretion of urokinase and TPA in our endothelial cell model. Fig 5, we compared IL-1, TNF-a, and estrogen as agonists as well as bradykinin and thrombin, both of which are known to stimulate release of TPA from endothelial cells. With urokinase as the secreted protein in question, there is no release with bradykinin but a time course is evident with thrombin (Fig 5, A) . Estradiol is negative at doses of 1 and 10 ng/mL, distinct from its positive effect on secretion of Hsp90. Both IL-1-b and TNF-a are clearly positive and here TNF-a is the more prominent. In short, thrombin, IL-1-b, and TNF-a stimulate urokinase secretion from endothelial cells while estrogen and bradykinin do not. It should be noted that bradykinin has been used as a stimulus for the secretion of TPA from human vasculature; however, the concentration required was 10-to 100-fold greater. 26 TPA secretion was not augmented beyond control values by any agent, but there is a gradual secretion of TPA into the milieu at baseline conditions.
As shown in
Comparison of factor XII activation in the fluid phase by kallikrein and plasmin If significant amounts of urokinase were secreted, conversion of plasminogen to plasmin will result. The key controls for inhibition of fibrinolysis are inactivation of urokinase by PAI-2 and inactivation of plasmin by a 2 antiplasmin 27 and a 2 macroglobulin. 28 Enzymatic activation of factor XII in plasma is rapid, 29 and here we compare the 2 known possibilities for feedback enzymatic activation, namely, kallikrein and plasmin. For this experiment, the synthetic substrate used is glu-gly-argp-nitroanilide rather than pro-phe-arg p-nitroanilide because the glu-gly-arg substrate is not cleaved by plasmin at all, and is cleaved by kallikrein only at concentrations beyond those used in these experiments. It is, however, an excellent substrate for factor XIIa, a little less sensitive than the pro-phe-arg substrate, but far more specific. 30 The factor XII control is shown in Fig 6, A, and did not autoactivate within the 2-hour interval of the experiment. Maximal activation is seen with kallikrein at 0.31 or 0.16 mg/mL and only slightly less at 0.08 mg/mL. Maximal activation with plasmin is seen at 5 mg/mL and as the dose is progressively halved down to 0.62 mg/mL, the rate of activation declines (Fig 6, B) . We estimate the increased effectiveness of kallikrein/plasmin by weight to be approximately 20/1. Significant activation is noted within 1 minute but it decreases to seconds if factor XII is bound to a surface and kallikrein is bound to HK. 31, 32 Plasmin is not augmented by HK.
DISCUSSION
Hsp90 is secreted by cultured endothelial cells constitutively and activates the HK-prekallikrein complex to form kallikrein. This reaction is stoichiometric and zinc dependent, with attachment to HK, primarily (Fig 1) , to form a trimolecular complex. Secretion of Hsp90 by endothelial cells can be augmented by Il-1-b, TNF-a, and estrogen; thus, infection and estrogen exposure can potentially trigger or augment swelling not only in HAE types I and II, but estrogen, in particular, may contribute in this fashion to patients with HAE with normal C1 inhibition regardless of whether the factor XII mutation is present or not. 33 Because estrogen also increases factor XII levels, 3, 4 it may initiate or augment attacks of angioedema in all types of HAE. At least 90% of HAE-N patients are women and episodes are strikingly dependent on additional exogenous estrogen. 19 Our observation of decreased levels of PAI-2 in many patients with HAE-N, with (HAE-XII) or without (HAE-U) a factor XII FIG 5 . Urokinase and tissue plasminogen activator release from endothelial cells. Cells were grown in 24-well plate with 0.5 mL medium. When confluent, the cells were washed and changed to serum-free medium for treatment with thrombin, bradykinin, IL-1-b, TNF-a, and estradiol and incubated at 378C. Samples were collected at indicated times and the levels of urokinase (A) and TPA (B) released was measured by ELISA. The experiments were performed 3 times with duplicate wells, and the graphs represent mean 6 SD. *Indicate values that are significantly higher than control (P < .001).
mutation, suggests diminished inhibition of fibrinolysis. We therefore tested secretion of urokinase from endothelial cells and found striking augmentation of secretion by IL-1-b or TNF-a, but not estrogen. We did not observe synergism with a combination of IL-1-b and TNF-a at doses of either 1 or 10 ng/ mL. Although bradykinin and thrombin are known stimulators of TPA secretion, the 2 cytokines and estrogen were negative when tested under the same conditions used for Hsp90 release (data not shown).
All our efforts point to a possibility that attacks of angioedema in HAE can be initiated by activation of HK-prekallikrein followed by recruitment of factor XII to yield a tremendous burst in reaction rate. But this order is the opposite of what is typically assumed. In contrast to fluid-phase activation, factor XII alone does not autoactivate under the conditions used even if prekallikrein is added. 34 This is likely in part because it is HK that interacts with the cell surface, and not prekallikrein, and it augments the ability of any factor XIIa present to convert prekallikrein to kallikrein. 32, 35 Elucidating a role for fibrinolysis requires much more work but elevated circulating levels of D-dimer 21, 22 depend on plasmin cleavage of fibrin and a low PAI-2, in many patients with HAE-N, points to a lesser control of urokinase-dependent fibrinolysis in such patients. 35 Although kallikrein is a more efficient activator of factor XII than is plasmin (Fig 6) , and is augmented by the presence of HK, 36 de Maat et al 37 have demonstrated that mutant factor XII in a subpopulation of patients with HAE-XII is more susceptible to cleavage and activation by plasmin compared with wild-type factor XII. This can be an important mechanism for excessive bradykinin formation 38 in such patients. The augmented secretion of urokinase by cytokines is a first step to determining a source of enzyme for conversion of plasminogen to plasmin because the prourokinase that circulates in plasma is at an extremely low level. 39 It should be noted, however, that plasma prourokinase can be activated by plasma kallikrein to urokinase 39, 40 so that some contribution within the plasma itself is possible.
In summary, our studies suggest the possibility that attacks of angioedema in the various types of HAE could be initiated or stimulated by activation of endothelial cells to release factors that affect the bradykinin-forming pathways directly (release of Hsp90 to activate the prekallikrein-HK complex to form kallikrein) or indirectly (release of urokinase which, in turn, converts plasminogen to plasmin followed by activation of factor XII, particularly mutant factor XII). A figure depicting the latter mechanism can be found in our recent publication.
